Qube Research & Technologies (QRT)
TAK icon

Qube Research & Technologies (QRT)’s Takeda Pharmaceutical TAK Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.4M Buy
+2,207,432
New +$36.5M 0.03% 633
2026
Q1 		– Sell
-197,507
Closed -$3.08M – 4116
2025
Q4 		$3.08M Sell
197,507
-1,578,338
-89% -$22.6M ﹤0.01% 2033
2025
Q3 		$26M Buy
1,775,845
+1,426,184
+408% +$21.2M 0.03% 769
2025
Q2 		$5.41M Buy
349,661
+55,962
+19% +$827K 0.01% 1649
2025
Q1 		$4.37M Buy
293,699
+113,761
+63% +$1.59M 0.01% 1608
2024
Q4 		$2.38M Buy
179,938
+49,821
+38% +$684K ﹤0.01% 1807
2024
Q3 		$1.85M Buy
+130,117
New +$1.85M ﹤0.01% 1785
2024
Q2 		– Sell
-114,209
Closed -$1.59M – 4694
2024
Q1 		$1.59M Sell
114,209
-319,309
-74% -$4.64M ﹤0.01% 1877
2023
Q4 		$6.19M Buy
433,518
+146,813
+51% +$2.08M 0.01% 932
2023
Q3 		$4.44M Sell
286,705
-444,953
-61% -$6.89M 0.01% 990
2023
Q2 		$11.5M Buy
731,658
+394,761
+117% +$6.47M 0.04% 501
2023
Q1 		$5.55M Buy
+336,897
New +$5.37M 0.02% 639
2022
Q2 		– Sell
-218,322
Closed -$3.13M – 3108
2022
Q1 		$3.13M Buy
218,322
+15,874
+8% +$233K 0.03% 655
2021
Q4 		$2.76M Buy
202,448
+7,368
+4% +$103K 0.02% 717
2021
Q3 		$3.19M Buy
+195,080
New +$3.27M 0.04% 546
2021
Q2 		– Sell
-188,713
Closed -$3.45M – 2786
2021
Q1 		$3.45M Sell
188,713
-9,598
-5% -$173K 0.05% 454
2020
Q4 		$3.61M Sell
198,311
-280,588
-59% -$4.92M 0.05% 403
2020
Q3 		$8.54M Buy
478,899
+352,389
+279% +$6.42M 0.12% 211
2020
Q2 		$2.27M Buy
+126,510
New +$2.27M 0.03% 622
2020
Q1 		– Sell
-94,412
Closed -$1.86M – 1644
2019
Q4 		$1.86M Buy
94,412
+64,525
+216% +$1.23M 0.06% 384
2019
Q3 		$514K Sell
29,887
-2,913
-9% -$50.4K 0.34% 85
2019
Q2 		$581K Buy
+32,800
New +$597K 0.14% 160
2019
Q1 		– Sell
-69,304
Closed -$1.17M – 471
2018
Q4 		$1.17M Buy
+69,304
New +$1.17M 0.5% 28

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Qube Research & Technologies (QRT)'s TAK Position: Q2 2026 in Review

Qube Research & Technologies (QRT) opened a new position in Takeda Pharmaceutical (TAK) in Q2 2026: 2,207,432 shares worth $35.4M. The stake represents 0.03% of the portfolio and ranks #633 among its holdings. This is a return to the name: Qube Research & Technologies (QRT) previously reported a position in TAK as recently as Q4 2025.

Qube Research & Technologies (QRT) first reported a position in TAK in Q4 2018 and has held it in 23 quarters since. 375 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Qube Research & Technologies (QRT) held 2,207,432 shares of Takeda Pharmaceutical worth $35.4M as of Q2 2026.
  • Takeda Pharmaceutical was a new Qube Research & Technologies (QRT) position in Q2 2026.
  • Takeda Pharmaceutical made up 0.03% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #633 holding.
  • Qube Research & Technologies (QRT) first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 23 quarters since.
  • 375 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.